Effect of atorvastatin on interleukins and prostaglandin E2 in the kidney of type 1 diabetic rats
The aim of the study was to evaluate a possible effect of atorvastatin on renal interleukins (ILs) and prostaglandin E2 (PGE2) in type 1 diabetic rats.
Thirty-two male rats from a local Wisterderived strain were included in this prospective study and were classified into four groups. Each group consisted of eight animals: Group 1, non-diabetic negative controls; Group 2, diabetic positive controls; Group 3, non-diabetic rats receiving atorvastatin for 4 weeks; and Group 4, diabetic rats receiving atorvastatin for 4 weeks. At the end of the designated period, the animals were sacrificed by cervical dislocation, and the kidneys were excised and homogenized to determine the level of IL-1β, IL-6, IL-10, and PGE2. The study duration was from June 2015 to May 2016 at Al-Ahlyya Amman University, Amman, Jordan.
In the kidneys of rats with streptozotocin-induced diabets, the levels of cytokines IL-1β, IL-6, IL-10, and PGE2 were significantly elevated above those of the control group. This clearly showed a detrimental effect of diabetes on the kidney. Treatment of diabetic rats with atorvastatin caused a decrease in all evaluated cytokines to levels near control values.
Our data suggest that atorvastatin has the potential to protect or attenuate diabetes-induced renal injury. However, the possible protective effect of atorvastatin should be supported by clinical evidence.
Key wordscytokines prostaglandin atorvastatin interleukin
Unable to display preview. Download preview PDF.
- 3.Shelton RJ, Velavan P, Nikitia NP, et al. Clinical trials update from the American Heart Association meeting: ACORN-CSD primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMENI, vitamin E meta-analysis, ESCAPE, CARP and SCD-HeFT cost-effectiveness study. Eur J Heart Fail 2005; 7: 127–35.CrossRefPubMedGoogle Scholar
- 6.Donate-Correa J, Martín-Nú˜nez E, Muros-de-Fuentes M, Mora-Fernández C, and Navarro-González J. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res 2015; Article ID 948417:9.Google Scholar
- 19.Botteridge DJ, Cannena R. The diabetogenic action of statins-mechanisms and clinical implications. Nat Rev Endocrinol 2016; 12: 99–110.Google Scholar
- 21.Rosa MS, Pinto AM. Cytokines. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics, 4th ed.. St Louis: Elsevier Saunders, 2006, 645.Google Scholar
- 22.Burtis CA, Ashwood ER. Lipids, lipoproteins, apolipoproteins and others cardiovascular risk factors, prostaglandins. In: Bruns DE, ed. Tietz textbook of clinical chemistry and molecular diagnostics, 6th ed.. St Louis: Elsevier Saunders, 2008, 409.Google Scholar
- 24.Lim A, and Tesch G. Inflammation in diabetic nephropathy. Mediators of Inflammation 2012, 2012:Article ID 146154.Google Scholar